Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:PRTK
- CUSIP: 89354M10
- Web: www.paratekpharma.com
Capitalization:- Market Cap: $586.82 million
- Outstanding Shares: 27,485,000
Average Prices:- 50 Day Moving Avg: $23.09
- 200 Day Moving Avg: $19.51
- 52 Week Range: $9.80 - $26.10
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.80
- P/E Growth: -0.02
Sales & Book Value:- Annual Revenue: $46,999.00
- Price / Sales: 11,812.95
- Book Value: $3.30 per share
- Price / Book: 6.12
Profitability:- EBIDTA: ($103,850,000.00)
- Return on Equity: -124.07%
- Return on Assets: -75.27%
Debt:- Debt-to-Equity Ratio: 0.46%
- Current Ratio: 7.66%
- Quick Ratio: 7.66%
Misc:- Average Volume: 672,222 shs.
- Beta: 0.91
- Short Ratio: 3.84
Frequently Asked Questions for Paratek Pharmaceuticals (NASDAQ:PRTK)
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) released its quarterly earnings results on Thursday, May, 4th. The company reported ($1.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.20) by $0.06. The firm had revenue of $0.02 million for the quarter. View Paratek Pharmaceuticals' Earnings History.
Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?
8 brokerages have issued 1 year price objectives for Paratek Pharmaceuticals' shares. Their predictions range from $23.00 to $56.00. On average, they expect Paratek Pharmaceuticals' share price to reach $39.50 in the next twelve months. View Analyst Ratings for Paratek Pharmaceuticals.
What are analysts saying about Paratek Pharmaceuticals stock?
Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "OASIS-2 study met all of its primary and secondary endpoints required to support approval for this indication by the FDA and EMA. This represents the third positive Phase 3 registration study of omadacycline (the other two were skin and pneumonia)." (7/17/2017)
- 2. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (4/21/2017)
- 3. Robert W. Baird analysts commented, "Though sarecycline is not a key driver, it provides a potential source of non-dilutive financing and further validates Paratek's ability to develop a once daily, well tolerated, tetracycline-derived antibiotic. Looking ahead, we expect continued momentum with focus on key upcoming data readouts from two Phase 3 studies of omadacycline in 2Q17, supporting filing in 1H18, and we reiterate our Outperform rating." (3/27/2017)
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), Achaogen (AKAO), PTC Therapeutics (PTCT), NeuroDerm (NDRM), ZIOPHARM Oncology (ZIOP), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX) and Epizyme (EPZM).
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Michael F. Bigham CPA, Chairman of the Board, Chief Executive Officer
- Evan Loh M.D., President, Chief Operating Officer, Chief Medical Officer, Director
- Douglas W Pagan, Chief Financial Officer
- William M. Haskel, Senior Vice President, General Counsel, Corporate Secretary
- Regina D. Paglia, Senior Vice President - Human Resources
- Jeanne Jew, Senior Vice President - Business Development
- Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations
- Rajesh Padmanabhan, Vice President - Information Technology
- Stephen Villano M.D., Vice President - Clinical and Medical Affairs
- Adam Woodrow, Vice President and Chief Commercial Officer
Who owns Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include InterWest Venture Management Co (1.86%), Appleton Partners Inc. MA (0.03%) and Fox Run Management L.L.C. (0.03%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega and Michael Bigham. View Institutional Ownership Trends for Paratek Pharmaceuticals.
Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Appleton Partners Inc. MA and Fox Run Management L.L.C.. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Evan Loh, Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.
How do I buy Paratek Pharmaceuticals stock?
Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $20.20.
MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.13) |
| Consensus Price Target: | $39.50 (95.54% upside) |
Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/18/2017 | HC Wainwright | Boost Price Target | Positive -> Buy | $36.00 -> $43.00 | High |  |
| 7/17/2017 | Cantor Fitzgerald | Set Price Target | Buy | $50.00 | High | |
| 5/18/2017 | Raymond James Financial, Inc. | Initiated Coverage | Strong-Buy -> Strong-Buy | $36.00 | High | |
| 4/4/2017 | Guggenheim | Set Price Target | Buy | $38.00 | Medium | |
| 4/4/2017 | BTIG Research | Boost Price Target | Buy | $47.00 -> $56.00 | Medium | |
| 4/4/2017 | Robert W. Baird | Reiterated Rating | Outperform | $40.00 | Medium | |
| 4/3/2017 | Wedbush | Reiterated Rating | Outperform -> Outperform | $30.00 | High | |
| 11/3/2016 | Leerink Swann | Reiterated Rating | Buy | $23.00 | N/A | |
| 6/17/2016 | Ladenburg Thalmann Financial Services | Boost Price Target | Buy | $46.00 -> $52.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)Earnings History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | ($1.20) | ($1.14) | | $0.02 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($1.33) | ($1.17) | | $0.03 million | View | Listen | |
| 11/2/2016 | | ($1.38) | ($1.04) | | | View | N/A | |
| 5/2/2016 | | ($1.25) | ($1.77) | | | View | N/A | |
| 2/23/2016 | Q4 | ($1.18) | ($1.20) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.91) | ($1.33) | | | View | Listen | |
| 8/5/2015 | Q215 | ($0.75) | ($0.94) | $3.62 billion | | View | N/A | |
| 4/2/2015 | Q1 | ($2.16) | ($0.74) | $0.13 million | $4.00 million | View | N/A | |
| 5/5/2014 | | ($0.18) | ($0.15) | | $0.42 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.21) | ($0.29) | $0.50 million | $0.32 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.42) | ($0.56) | | | View | N/A | |
| 11/12/2012 | Q312 | $0.06 | $0.25 | $8.37 million | $10.44 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)2017 EPS Consensus Estimate: ($3.47)
2018 EPS Consensus Estimate: ($3.13)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.15) | ($1.15) | ($1.15) |
| Q2 2017 | 1 | ($0.79) | ($0.79) | ($0.79) |
| Q3 2017 | 1 | ($0.86) | ($0.86) | ($0.86) |
| Q4 2017 | 1 | ($0.67) | ($0.67) | ($0.67) |
| Q1 2018 | 1 | ($0.86) | ($0.86) | ($0.86) |
| Q2 2018 | 1 | ($0.88) | ($0.88) | ($0.88) |
| Q3 2018 | 1 | ($0.52) | ($0.52) | ($0.52) |
| Q4 2018 | 1 | ($0.87) | ($0.87) | ($0.87) |
(Data provided by Zacks Investment Research)
Dividend History by Quarter for Paratek Pharmaceuticals (NASDAQ PRTK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/14/2014 | special | $1.33 | | 6/4/2014 | 5/26/2014 | 6/3/2014 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Paratek Pharmaceuticals (NASDAQ:PRTK)Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 75.67%
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Adam Woodrow | VP | Sell | 3,800 | $23.58 | $89,604.00 | |
| 7/5/2017 | Douglas W Pagan | CFO | Sell | 4,139 | $23.58 | $97,597.62 | |
| 7/5/2017 | Evan Loh | COO | Sell | 4,351 | $23.58 | $102,596.58 | |
| 7/5/2017 | Michael Bigham | Chairman | Sell | 5,075 | $23.58 | $119,668.50 | |
| 6/19/2017 | Douglas W Pagan | CFO | Sell | 4,595 | $25.00 | $114,875.00 | |
| 2/6/2017 | Douglas W Pagan | CFO | Sell | 3,405 | $15.09 | $51,381.45 | |
| 2/6/2017 | Evan Loh | COO | Sell | 3,106 | $15.09 | $46,869.54 | |
| 2/6/2017 | Michael Bigham | Chairman | Sell | 5,000 | $15.09 | $75,450.00 | |
| 6/27/2016 | Fund Iv L.P. Omega | Major Shareholder | Buy | 461,538 | $13.00 | $5,999,994.00 | |
| 6/23/2016 | Michael Bigham | CEO | Buy | 20,000 | $13.45 | $269,000.00 | |
| 12/11/2015 | Evan Loh | CMO | Buy | 2,300 | $16.87 | $38,801.00 | |
| 5/29/2015 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 20,580 | $30.75 | $632,835.00 | |
| 12/13/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 1,470 | $3.54 | $5,203.80 | |
| 12/11/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,490 | $3.55 | $37,239.50 | |
| 12/6/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 8,710 | $3.54 | $30,833.40 | |
| 12/4/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,120 | $3.50 | $24,920.00 | |
| 11/20/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,040 | $3.57 | $35,842.80 | |
| 11/12/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,190 | $3.53 | $25,380.70 | |
| 11/7/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 4,960 | $3.61 | $17,905.60 | |
| 10/30/2013 | Roumell Asset Management, Llc | Major Shareholder | Sell | 7,020 | $3.69 | $25,903.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Paratek Pharmaceuticals (NASDAQ:PRTK)
Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
| Source: |
|
| Date | Headline |
|---|
 | Paratek Puts Skin In The Infection Game - Seeking Alpha
seekingalpha.com - July 24 at 4:22 PM |
 | Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Expected to Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - July 21 at 10:18 PM |
 | Breakfast Technical Briefing on Biotech Stocks -- Aurinia Pharma, Esperion Therapeutics, Paratek Pharma, and Verastem
www.prnewswire.com - July 21 at 6:23 AM |
 | Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PRTK-US : July 20, 2017
finance.yahoo.com - July 21 at 6:23 AM |
| Paratek Antibiotic Candidate's Phase III Data Favorable
finance.yahoo.com - July 20 at 6:14 AM |
| Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017
finance.yahoo.com - July 20 at 6:14 AM |
 | Paratek Pharmaceuticals (PRTK) Says Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and ... - StreetInsider.com
www.streetinsider.com - July 18 at 7:32 AM |
| Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
finance.yahoo.com - July 18 at 7:31 AM |
| Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - July 17 at 7:15 PM |
| Paratek Pharmaceuticals, Inc. (PRTK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 10:49 AM |
| Is the Options Market Predicting a Spike in Paratek (PRTK) Stock?
finance.yahoo.com - July 12 at 7:09 AM |
 | Notable Monday Option Activity: NEWR, STT, PRTK - Nasdaq
www.nasdaq.com - July 11 at 6:47 AM |
| Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - July 8 at 1:44 PM |
| Evan Loh Sells 4,351 Shares of Paratek Pharmaceuticals, Inc. (PRTK) Stock
www.americanbankingnews.com - July 6 at 8:06 PM |
| Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chairman Sells 5,075 Shares of Stock
www.americanbankingnews.com - July 6 at 8:05 PM |
| Douglas W. Pagan Sells 4,139 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock
www.americanbankingnews.com - July 6 at 8:05 PM |
| Paratek Pharmaceuticals, Inc. (PRTK) VP Adam Woodrow Sells 3,800 Shares
www.americanbankingnews.com - July 6 at 8:04 PM |
| Biotech Movers: Paratek, Opko, Endo
finance.yahoo.com - July 1 at 6:42 AM |
| $7.50 Million in Sales Expected for Paratek Pharmaceuticals, Inc. (PRTK) This Quarter
www.americanbankingnews.com - June 29 at 9:50 AM |
| Zacks: Analysts Expect Paratek Pharmaceuticals, Inc. (PRTK) Will Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - June 27 at 6:20 PM |
| Cantor Fitzgerald Reaffirms "Overweight" Rating for Paratek Pharmaceuticals, Inc. (PRTK)
www.americanbankingnews.com - June 22 at 8:34 PM |
| Paratek Pharmaceuticals, Inc. (PRTK) CFO Douglas W. Pagan Sells 4,595 Shares
www.americanbankingnews.com - June 21 at 8:05 PM |
| Paratek Pharmaceuticals, Inc. (PRTK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 20 at 8:58 AM |
| ETFs with exposure to Paratek Pharmaceuticals, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 9:03 AM |
| Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : June 14, 2017
finance.yahoo.com - June 14 at 11:51 PM |
| Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference - Nasdaq
www.nasdaq.com - June 14 at 8:45 AM |
| Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference
finance.yahoo.com - June 14 at 8:44 AM |
| Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : June 13, 2017
finance.yahoo.com - June 13 at 10:16 AM |
 | New Microbiology Data Reinforce Activity of Paratek's Omadacycline ... - GlobeNewswire (press release)
globenewswire.com - June 3 at 6:46 PM |
| New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections
finance.yahoo.com - June 3 at 6:46 PM |
| $7.50 Million in Sales Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter
www.americanbankingnews.com - June 3 at 8:18 AM |
| -$0.89 EPS Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter
www.americanbankingnews.com - June 1 at 4:20 PM |
| Short Interest in Paratek Pharmaceuticals Inc (PRTK) Rises By 12.0%
www.americanbankingnews.com - May 28 at 1:46 PM |
| Paratek Pharmaceuticals Inc (PRTK) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 26 at 7:59 AM |
| Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017 - GlobeNewswire (press release)
www.globenewswire.com - May 24 at 7:39 PM |
| Paratek Pharmaceuticals: The 1 Antibiotic Stock To Buy Now - Seeking Alpha
seekingalpha.com - May 22 at 6:29 PM |
| Paratek Pharmaceuticals Inc (PRTK) Research Coverage Started at Raymond James Financial, Inc.
www.americanbankingnews.com - May 18 at 10:56 PM |
| Analysts Offer Predictions for Paratek Pharmaceuticals Inc's FY2017 Earnings (PRTK)
www.americanbankingnews.com - May 12 at 12:33 PM |
| $7.5 Million in Sales Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter
www.americanbankingnews.com - May 10 at 11:14 AM |
| Analysts Expect Paratek Pharmaceuticals Inc (PRTK) Will Announce Earnings of -$1.08 Per Share
www.americanbankingnews.com - May 8 at 1:18 PM |
| Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July
finance.yahoo.com - May 8 at 11:56 AM |
| Wedbush Equities Analysts Boost Earnings Estimates for Paratek Pharmaceuticals Inc (PRTK)
www.americanbankingnews.com - May 8 at 8:21 AM |
| Paratek Pharmaceuticals Inc (PRTK) PT Set at $33.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 7 at 8:02 AM |
| Analysts Set Expectations for Paratek Pharmaceuticals Inc's Q1 2018 Earnings (PRTK)
www.americanbankingnews.com - May 5 at 5:32 PM |
| Paratek Pharmaceuticals Inc (PRTK) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - May 5 at 5:30 PM |
| Today's Research Reports on Arrowhead Pharmaceuticals and Paratek Pharmaceuticals Post Earnings
finance.yahoo.com - May 5 at 8:29 AM |
| Paratek Pharmaceuticals, Inc. (PRTK)
seekingalpha.com - May 5 at 12:34 AM |
| Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - May 5 at 12:34 AM |
| Investor Network: Paratek Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - May 5 at 12:34 AM |
| Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update - Yahoo Finance
finance.yahoo.com - May 4 at 7:32 PM |
Paratek Pharmaceuticals (PRTK) Chart for Tuesday, July, 25, 2017
